Contribution of anorexia to tissue wasting in cachexia

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 4, 2010, Pages 249-253

  Molfino, Alessio ^a,b   Laviano, Alessandro ^a   Fanelli, Filippo Rossi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anorexia; Cachexia; Ghrelin; Melanocortin; Muscle; Tissue wasting

Indexed keywords

ANOREXIA; ARTICLE; CACHEXIA; CHRONIC DISEASE; HUMAN; PATHOPHYSIOLOGY; SYNDROME; WASTING SYNDROME; WEIGHT REDUCTION;

ANOREXIA; CACHEXIA; CHRONIC DISEASE; HUMANS; SYNDROME; WASTING SYNDROME; WEIGHT LOSS;

EID: 78449262697     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833e4aa5     Document Type: Article

References (53)

1. Laviano A, Meguid MM, Cascino A, et al. Tryptophan in wasting diseases: At the crossing between immune function and behaviour. Curr Opin Clin Nutr Metab Care 2009; 12:392-397.
2. Hutton JL, Martin L, Field CJ, et al. Dietary patterns in patients with advanced cancer: Implications for anorexia-cachexia therapy. Am J Clin Nutr 2006; 84:1163-1170.
3. Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 2007; 33:156-165.
4. Laviano A, Meguid MM, Rossi Fanelli F. Cancer anorexia: Clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4:686-694.
5. Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80:299-307.
6. Lasheen W, Walsh D. The cancer anorexia-cachexia syndrome: Myth or reality? Support Care Cancer 2010; 18:265-272.
7. Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr 2008; 27:793-799.
8. Laviano A, Inui A, Marks DL, et al. Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab 2008; 295:E1000-E1008.
9. Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Ass 2010; 11:229-230.
10. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 2006; 21:229-233.
11. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050-1053.
12. Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: A meta-analysis. Am Heart J 2008; 156:13-22.
13. Vilaró J, Ramirez-Sarmiento A, Martinez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 2010. [Epub ahead of print]
14. Nishimura K, Tsukino M. Clinical course and prognosis of patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000; 6:127-132.
15. Benton MJ, Wagner CL, Alexander JL. Relationship between body mass index, nutrition, strength, and function in elderly individuals with chronic obstructive pulmonary disease. J Cardiopulm Reabil Brev 2010; 30:260-263.
16. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind randomized trial. Gastroenterology 2003; 124:1792-1801.
17. Merli M, Giusto M, Gentili F. Nutritional status: Its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010; 30:208-214.
18. de Carvalho L, Parise ER, Samuel D. Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation. J Gastroenterol Hepatol 2010; 25:391-396.
19. Bossola M, Tazza L, Luciani G. Mechanisms and treatment of anorexia in endstage renal disease patients on hemodialysis. J Ren Nutr 2009; 19:2-9.
20. Muscaritoli M, Molfino A, Chiappini MG, et al. Anorexia in hemodialysis: The possible role of des-acyl ghrelin. Am J Nephrol 2007; 27:360-365.
21. Molfino A, Laviano A, Chiappini MG, et al. Is des-acyl ghrelin contributing to uremic anorexia? Am J Clin Nutr 2007; 86:1550-1551.
22. Muscaritoli M, Molfino A, Bollea MR, Rossi Fanelli F. Malnutrition and wasting in renal disease. Curr Opin Clin Nutr Metab Care 2009; 12: 378-383.
23. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation- cachexia syndrome in chronic kidney disease patients: What is next? Semin Dial 2005; 18:365-369.
24. Morton JJ, Cummings DE, Baskin DJ, et al. Central nervous system control of food intake and body weight. Nature 2006; 443:289-295.
25. Abdel-Malek ZA. Melanocortin receptors: Their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001; 58:434-441.
26. Lu XY, Nicholson JR, Akil H, Watson SJ. Time course of short-term and longterm orexigenic effects of agouti-related protein (86-132). Neuroreport 2001; 12:1281-1284.
27. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145:2607-2612.
28. Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78:554-561.
29. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB J 2004; 18:439-456.
30. Wolfghang MJ, Lane MD. The role of hypothalamic malonyl-CoA in energy homeostasis. J Biol Chem 2006; 281:37265-37269.
31. Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia-cachexia syndrome: Cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7:427-434.
32. Von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007; 73:298-309.
33. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996; 270:R1394-R1402.
34. Tecot LH. Serotonin and the orchestration of energy balance. Cell Metab 2007; 6:352-361.
35. Heisler LK, Chowley MA, Tecot LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297:609-611.
36. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006; 51:239-249.
37. Zubareva OE, Krasnova IN, Abdurasulova IN, et al. Effect of serotonin synthesis blockage on interleukin-1β action in the brain of rats. Brain Res 2001; 915:244-247.
38. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33:415-424.
39. Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 2005; 9:737-752.
40. Muscaritoli M, Bossola M, Aversa Z, et al. Prevention and treatment of cancer cachexia. Eur J Cancer 2006; 42:31-41.
41. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008; 74:180-186.
42. Joppa MA, Gogas KR, Foster AC, Markinson S. Central infusion of the melanocortin receptor antagonist agouti-related peptide [AgRP(83-132)] prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007; 28:636-642.
43. Molfino A, Muscaritoli M, Cascino A, et al. Free tryptophan/large neutral amino acids ratios in blood plasma do not predict cerebral spinal fluid tryptophan concentrations in interleukin-1-induced anorexia. Pharmacol Biochem Behav 2008; 89:31-35.
44. Brito MN, Brito NA, Baro DJ, et al. Differential activation of the sympathetic innervation of adipose tissues by melanocortin receptor stimulation. Endocrinology 2007; 148:5339-5347.
45. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta-blockers: A pilot study. Int J Cardiol 2006; 106:319-322.
46. Nagaya M, Moriya J, Yasamura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110:3674-3679.
47. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128:1187-1193.
48. Peter JC, Lecourt AC, Wechering M, et al. A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: Effectiveness after peripheral and central administration. J Pharmacol Exp Ther 2010; 333:478-490. A recent study enhancing the role of MC4R antagonism to obtain positive peripheral and central effects in a murine model.
49. Weyermann P, Dallmann R, Magyar J, et al. Orally available selective melanocortin- 4 receptor antagonists stimulate food intake and reduce cancerinduced cachexia in mice. PLoS One 2009; 4:e4774. An outstanding experimental study in which the role of MC4R antagonisms, orally administered, offers a considerable advantage for cancer cachexia treatment.
50. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
51. Perboni S, Inui A. Appetite and gastrointestinal motility: Role of ghrelin-family peptides. Clin Nutr 2010; 29:227-234. This study analyzes and summarizes the most recent and relevant evidences of ghrelin-family molecules influencing appetite regulation
52. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology 2008; 149:827-835.
53. Ashby DR, Ford HE, Wynne KJ, et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009; 76:199-206. This paper describes an elegant clinical study in which ghrelin administration appears to be a really novel and efficient treatment against uremic anorexia.